TickerFacts.

RenovoRx, Inc. (RNXT): Cost of Revenue

Annual figures by period end, from SEC filings.

$327.0K
Year ended 2025-12-31
$308.0K
Trailing 12 months to 2026-06-30
2024-12-31: $02025-12-31: $327.0K$327.0K
2024-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$327.0Kn/a2026-03-30, From 2025-01-01
2024-12-31$0n/a2026-03-30, From 2024-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
RenovoRx, Inc. (RNXT)2025-12-31$327.0Kn/a
PetVivo Holdings, Inc. (PETV)2026-03-31$386.9K+181.0%
SeaStar Medical Holding Corp (ICU)2025-12-31$53.0Kn/a
Sintx Technologies, Inc. (SINT)2025-12-31$557.0K-31.3%
Flyte Aviation, Inc. (VJET)2025-12-31$63.0K+50.0%
EBR Systems, Inc. (NONE.)2025-12-31$1.13Mn/a
Harvard Apparatus Regenerative Technology, Inc. (HRGN)2025-12-31$646.0K+139.3%
Vycor Medical Inc (VYCO)2025-12-31$302.3K+81.2%
Co-Diagnostics, Inc. (CODX)2025-12-31$222.4K-77.7%

Compare RNXT, PETV, ICU, SINT side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗